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Abstract
Background: Effectiveness of ART regimens strongly depends upon complex interactions between the selective pressure of
drugs and the evolution of mutations that allow or restrict drug resistance.
Methods: Four clinical isolates from NRTI-exposed, NNRTI-naive subjects were passaged in increasing concentrations of NVP
in combination with 1 mM 3 TC and 2 mM ADV to assess selective pressures of multi-drug treatment. A novel parameter
inference procedure, based on a stochastic viral growth model, was used to estimate phenotypic resistance and fitness from
in vitro combination passage experiments.
Results: Newly developed mathematical methods estimated key phenotypic parameters of mutations arising through
selective pressure exerted by 3 TC and NVP. Concentrations of 1 mM 3 TC maintained the M184V mutation, which was
associated with intrinsic fitness deficits. Increasing NVP concentrations selected major NNRTI resistance mutations. The
evolutionary pathway of NVP resistance was highly dependent on the viral genetic background, epistasis as well as
stochasticity. Parameter estimation indicated that the previously unrecognized mutation L228Q was associated with NVP
resistance in some isolates.
Conclusion: Serial passage of viruses in the presence of multiple drugs may resemble the selection of mutations observed
among treated individuals and populations in vivo and indicate evolutionary preferences and restrictions. Phenotypic
resistance estimated here ‘‘in silico’’ from in vitro passage experiments agreed well with previous knowledge, suggesting
that the unique combination of ‘‘wet-’’ and ‘‘dry-lab’’ experimentation may improve our understanding of HIV-1 resistance
evolution in the future.
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Introduction
Antiretroviral drug resistance [1] limits therapeutic options,
clinical benefit and increases the risk of clinical progression [2].
Recommended first-line ART regimens consist of one non-
nucleoside reverse transcriptase inhibitor (NNRTI) combined
with two nucleoside reverse transcriptase inhibitors (NRTIs) [3].
All drugs within these combinations exert their effect on the HIV-
1 reverse transcriptase. Nevirapine (NVP), the first approved
NNRTI, binds directly to reverse transcriptase (RT) (the NNRTI
binding pocket), leading to conformational inflexibility [4] and
inhibition of enzymatic action [5]. NVP is used frequently to
prevent the transmission of HIV-1 from mother to child [6].
Lamivudine (3 TC) is the most commonly used NRTI. Its
triphosphate (3 TC-TP) competes with endogenous deoxycytosine
triphosphate for incorporation into the nascent viral DNA during
reverse transcription, where it inhibits HIV DNA elongation [7].
Adefovir (ADV) is an adenosine-monophosphate analogue, which
in diphosphate form, acts as a chain-terminator competing with
deoxyadenosine triphosphate for incorporation into viral DNA.
Although not approved by the FDA for treatment of HIV [8], it is
closely related to tenofovir disoproxil fumarate (TDF) a preferred
nucleotide RT inhibitor that is currently recommended as a key
component in first-line HAART [9].
Resistance to NVP, 3 TC and ADV is attributed to distinct
mutations. NVP resistance mutations within the NNRTI binding
pocket decrease NVP binding to RT by means of steric hindrance
[10]. Lamivudine (3 TC) resistance conferred by the M184V
mutation, decreases the affinity of 3 TC-TP for the primer/
template complex during reverse transcription [7]. In contrast,
ADV (and tenofovir) resistance selectively decreases incorporation
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of ADV phosphonate into viral DNA [11,12], associated with
mutations at K70E and K65R.
Different mutational trajectories may arise during combination
therapy, which may be altered by pre-existing mutations through
epistatic constraints and genetic bottlenecks [13,14]. In the context
of combination therapy, selective pressures drive evolutionary
pathways, consideration of which may optimize strategic sequenc-
ing of ART regimens [1,15]. Furthermore, the preservation of
mutations that limit viral fitness and replicative capacity [16,17]
provide for significant improvement in clinical and immunological
outcomes among drug-experienced patients [18].
To understand drug resistance during combination antiviral
drug treatments, an in vitro assay [19] was established in stimulated
PBMC infected with virus isolates from 4 NRTI-experienced (but
NNRTI-naive) patients. Mutations were selected by passage in
different combinations and concentrations of ADV, 3 TC and
NVP and viral fitness and resistance were estimated on the basis of
a stochastic model of viral growth.
Materials
HIV Strains
As described previously [19], clinical isolates were derived from
frozen samples. The primary clinical isolates were derived from 4
individuals who had previously received NRTI and protease
inhibitors, but who had never been exposed to NNRTIs. The
baseline RT mutations (as compared to the Los Alamos consensus
Hxb2) up to RT amino acid position 300 can be found in Table 1.
Cells and Cell Culture
HIV-negative donor PBMC from the Stanford Blood Bank
were cultured in RPMI medium containing 15% heat-inactivated
fetal calf serum, IL-2, PenStrep, and L-Glu and stimulated for 2–3
days with phytohemagglutinin (Sigma, St. Luis, MO) [20–22].
Test Compounds
Nevirapine (NVP) was kindly provided by Boehringer Ingelheim
(Ridgefield, CT), lamivudine (3 TC) by GlaxoSmithKline (Re-
search Triangle Park, NC), and adefovir (ADV) by Gilead (Foster
City, CA).
Virological Methods
Passage Experiments
The serial combination passage experiments with isolates #1–
#5 were conducted as follows [19]: (A) no drugs were added to the
media, (B) 1 mM 3 TC and 2 mM ADV were added and
maintained, (C) NVP was added and concentrations were doubled
with each passage (0.01 mM NVP during the first passage up to
20.48 mM during the last passage), (D) 2 mM ADV and increasing
concentrations of NVP were added, (E) 1 mM 3 TC and increasing
concentrations of NVP were added and (F) 1 mM 3 TC and 2 mM
ADV and increasing concentrations of NVP were added to the
medium, see Figure 1. Isolates #2 and #3 were derived from the
same individual but were run independently in experimental set-
ups C, D & E. For each experimental set-up (A–F), 12 single-
passage experiments were run, in total 5* 3* 12+4* 3* 12 = 324
single-passage experiments with a median duration of 21 days,
respectively. With each passage-experiment in C, D, E and F, the
concentration of NVP was doubled. The NVP starting dose was
0.01 mM, below the previously reported IC50 of NNRTI-naı¨ve
isolates (around 0.1 mM [23]). The final concentration was 2048-
fold (20.48 mM), below reported cytotoxic levels [23]. Cultures
were passaged as previously described [19]. Viral growth was
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Figure 1. Summary of passage experiments with sequencing data. The illustration provides a complete review of RT sequence changes
under the following experimental set-ups: A: no drugs were added to the media, B: [1 mM] 3 TC and [2 mM] ADV were added and maintained, C: NVP
was added and concentrations were doubled for each passage (0.01 mM NVP during the first passage up to 20.48 mM during the last passage), D:
[2 mM] ADV and increasing concentrations of NVP were added, E: [1 mM] 3 TC and increasing concentrations of NVP were added and F: [1 mM] 3 TC
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monitored using a p24 antigen assay (Abbott Laboratories,
Chicago, IL). At p24 ELISA values$36104 pg/ml, the cultures
were passaged: at levels ,36104 pg/ml, cultures were split, and
2.5 million PBMCs were replaced by new donor PBMC in media
containing the respective drugs in the same molar concentration.
Supernatant to infect new cells was adjusted by p24 values
obtained prior to passage.
ABI Sequencing
Population-based sequencing of amplified cDNA from viral
RNA was performed as described previously [19,24]. cDNA was
obtained using Superscript-One-Step RT-PCR reagent (Life
Technologies, Gaithersburg, MD). First-round nested PCR
primers were RT-21 [25] and MAW-26 [24], second-round
primers were PRO-1 [26] and RT-20 [25]. A d-Rhodamine
labeled terminator kit (PE Applied Biosystems, Warrensburg, UK)
and the previously described primers RT-a, RT-b (forward), RT-y
and HXBR2-89 (reverse) [27] were used for sequencing (ABI
Model 377 equipment and software). After alignment, proofread-
ing, and editing, sequence data were compared to baseline and
earlier passages of virus. Any change relative to wild type Hxb2
[28] sequence was defined as mutation. Any mutation back towards
Hxb2 was defined as a reversal, even if it was not ‘‘all the way
back’’.
Mathematical Methods
Novel mathematical methods were developed in order to
quantitatively estimate key phenotypic attributes from the
experimentally observed viral growth kinetics, by minimizing the
residual error e between experimental- and model-predicted virus
passage times. The estimated phenotypic attributes include the fold
resistance towards NVP, FR qð Þ, and the fitness deficitsf (q) for
mutational events q occurring during the respective passage
experiments. Furthermore, the growth rate of the respective
baseline isolate r1, its susceptibility towards NVP (IC50) and the
probability rNRTI to encounter inhibition by NRTIs (ADV or
3 TC) with intensity gNRTI (explained below) were estimated.
The viral growth model is introduced below. Based on the viral
growth model, passage times were computed to derive an objective
function suited for parameter estimation from the available
experimental data. Finally, a large-scale model selection technique
was used to find the most informative/relevant set of phenotypic
parameters and the robustness of the parameter estimation
procedure was assessed. The source code for the developed
methods is provided in the Material S1, with a short description of
the code.
Basic Viral Growth Model
We assumed a simple-birth Markov model [29], combining the
intermediate steps of target cell infection, pro-viral integration,
virus release, and virus maturation (e.g. see [30] for an overview).
Target cell concentrations were held constant during the
experiments (see Virological Methods), which reduces the infection
to first order kinetics. Furthermore, the absence of immune
responses in vitro allows the assessment of virus growth in the
absence of the immunologic confounders typically encountered
in vivo. For each virus isolate we could therefore model viral
growth kinetics with rate constant r j,pð Þ, where the index j refers
to the experiment j[ A . . .Ff g and the index p refers to the passage
number, i.e. passage p[ 1:::12f g, as shown in Fig. 1. For example,
isolate #1 is assumed to grow at rate r C,7ð Þin experiment C at
passage 7, i.e. in the presence of 0.32 mM NVP and after having
acquired mutation Y188 C (see Fig. 1C). As explained in the
example, the viral growth with rate constant r j,pð Þ is determined
by the presence of baseline mutations, by the presence of drugs at
different concentrations, and by mutational events q[Q j,pð Þ,
arising throughout the course of the experiment (selection/de-
selection of mutations). We modelled their simultaneous effects as
described previously [31]:
r j, pð Þ~r1: 1{gNVP j, pð Þð Þ|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
inhibition by NVP
: f j, pð Þ|ﬄﬄ{zﬄﬄ}
fitness
: 1{gNRTI j, rNRTIð Þð Þ|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
stoch: effect of low{doseNRTI
, ð1Þ
where r1 denotes the growth rate of the baseline viral isolate in
the absence of drugs. The parameter 1{gNVP j,pð Þð Þ denotes the
effect of NVP on viral growth kinetics in experiment j, in passage
p. It holds that 0ƒ 1{gNVP j,pð Þð Þƒ1, i.e. when the drug is very
efficient, gNVP j,pð Þ will be close to 1 (computation outlined below).
The fitness deficit of the viral strain encountered in experiment j,
passage p is denoted byf j,pð Þ. If the strain is very fit, f j,pð Þ will be
close to 1, if it is very unfit, it will be close to 0 (computation
outlined below). The parameter gNRTI j,rNRTIð Þ denotes the
intensity of the NRTI-effect (ADV/3TC effects) on viral growth
in experimental set-up j, which was estimated to be 0ƒgNRTIƒ1
with probability 0ƒrNRTIƒ1 when NRTIs were added (exper-
imental set-ups j [ B, D, E, Ff g) and which was set to
gNRTI~0, if NRTIs were not added (experimental set-up:
j[ A,Cf g). Note, that the concentrations of NRTIs were
maintained throughout an experimental set-up j, in contrast to
NVP concentrations, which were increased in consecutive
passages p. Different models for ADV/3TC effects were
compared: (i) assigning individual ‘‘noise effects’’ to ADV and
3TC respectively, (ii) assigning an isolated ADV effect or (iii) a
3TC effect versus (iv) a model that assigned an NRTI-effect if one
of the inhibitors was present. The comparison suggested that
model (iv) was best suited to describe the data. We therefore
assigned an NRTI-effect, if at least one of the inhibitors (ADV or
3TC) was present in experimental set-up j.
Drug Effects and Fitness
The effect of NVP on viral growth was modelled according to
the standard model of pharmacological action (Emax-model) [32]:
1{gNVP j,pð Þ~
IC50:PqEQ j,pð Þ FR qð Þ
IC50:PqEQ j,pð Þ FR qð Þz NVP j,pð Þ½ 
, ð2Þ
where FR qð Þ denotes the fold resistance to NVP exerted by a
single mutation q[Q j,pð Þ selected during the course of experiment
j until passage p. [NVP (j, p)] denotes the concentration of NVP
added in passage p of experiment j and IC50 refers to the fifty
percent inhibitory concentration of the baseline isolate.
and [2 mM] ADV and increasing concentrations of NVP were added to the medium. Individual isolates #1 to #5 are indicated above the columns.
Sequence changes listed are indicated in the rows that correspond to the passage number where they were first observed. NVP concentrations used
in the respective passage experiment are listed on the right in units mM. Any mutation away from wild-type (Hxb2 strain) is indicated by a rightward-
pointing arrow, whereas reversal to wild-type is indicated by a left-ward pointing arrow. All sequence changes (novel mutations and reversals)
persisted throughout passage 12.
doi:10.1371/journal.pone.0061102.g001
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Accordingly, the fitness deficit f j,pð Þ of the respective viral
strain present at passage p during experiment j was modelled
according to:
f j,pð Þ~ P
q[Q j,pð Þ
f qð Þ, ð3Þ
where f (q) denotes the relative fitness of the single mutation
q[Q j,pð Þ, that has not yet been reversed/de-selected until passage
p in experiment j. Note, that all mutational events q[Q j,pð Þ that
have arisen until a particular passage p[ 1:::12f g in experiments
j[ AFf g were taken into account simultaneously. For example, in
experimental set-upj = A for isolate #2, at passage p = 12 (see
Fig. 1A) we took into account both the phenotypic effects of
q1 = Mr184 V, which arose earlier at passage 4, as well as q2 =
Nr67 S, see eq. (1)-(3).
Passage Times
In the experiments (see Virological Methods), viral growth which
exceeded a threshold Vtend was recorded, i.e. the time required for
a viral population to exceed a p24 ELISA signal of$36104 pg/ml
(see Fig. 2). This time can be referred to as passage time. Having a
model for the growth of virus (see eqs.(1)-(3)), we can compute
these quantities from the model as well, which allows us to perform
parameter estimation. The passage experiments can be modelled
as a Markov process [33], for which the time elapsed (in days)
before the size of the virus population attains the threshold Vtend is
referred to as passage time (in mathematical literature it is also
referred to as first passage time or first hitting time) [34]. Because the
passage times are random variables, we are interested in their
statistical moments. The first statistical moment of the probability
distribution of the passage time corresponds to its mean value (the
Figure 2. Box plot of single passage times for virus isolate#1,#2/3,#4 &#5 during experimental set-ups A–F as indicated on the
x-axis. The solid red horizontal lines indicate the respective median passage times, whereas the boxes surrounding them indicate the range
encompassed by the 25th and 75th percentiles. The whiskers denote the most extreme data points, which are not considered outliers and the black
dots indicate outliers. A: Viral passage times for isolate#1. B: Viral passage times for isolate#2&3 (combined). C: Viral passage times for isolate#4. D:
Viral passage times for isolate #5.
doi:10.1371/journal.pone.0061102.g002
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mean passage time), whereas the square root of the second
(centralized) statistical moment corresponds to its standard
deviation [35].
In the passage experiments described above (see Virological
Methods), virus was diluted 100-fold (100 mL supernatant in 10 mL
media) and the time to an initial p24 ELISA signal ($36104 pg/ml)
was recorded. We therefore infer that Vtend~100:Vt0; i.e. the
concentration of virus has to increase by a factor of 100 with respect
to the virus concentration used at the initiation of a passage Vt0. For
any passage p during experimental setting j the mean passage time can
be computed according to [36]:
TVt0?Vtend j,pð Þ~
X100:Vt0
k~Vt0
tk j,pð Þ, ð4Þ
where tk j,pð Þ~1= k:r j,pð Þð Þ denotes the waiting time in state k
(number of viral particles). Substituting eq.(1), we get
TVt0?Vtend j,pð Þ
~
1
1{gNVP j,pð Þð Þ:f j,pð Þ: 1{gNRTI j,pNRTIð Þð Þ
  X100Vt0
k~Vt0
1
k:r1
:
ð5Þ
By further substituting eqs. (2)–(3), the equation above allows to
express the mean passage time in terms of the IC50, fitness values
f qð Þ, fold resistance FR qð Þ, basic growth rate r1, rNRTI and
gNRTI, which will be exploited later for parameter estimation.
The raw second moment of the passage time distribution can be
computed according to [36]:
VVt0?Vtend j,pð Þ
~
X100:Vt0
k~Vt0
2:TVt0?k j,pð Þ
k:r j,pð Þ ~2
1
r j,pð Þ
 2 X100:Vt0
k~Vt0
1
k
Xk
s~Vt0
1
s
,
ð6Þ
where eq.(1)-(3) can again be substituted. The raw second moment
(eq.(6)) can be centralized. The square root of this centralized
second moment yields the standard deviation of the passage times [37].
Thus, the above analytical expressions enable to compute the mean
m j,pð Þ and standard deviation s j,pð Þ of the time required for a single-
passage p in an experiment j according to
m j,pð Þ~TVt0?Vtend j,pð Þ, ð7Þ
s j,pð Þ~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
VVt0?Vtend j,pð Þ{TVt0?Vtend j,pð Þ
2
q
: ð8Þ
Objective Function
The above derived mean m j,pð Þ and standard deviation s j,pð Þ of the
passage times correspond to a single passage p in an experiment j.
Experimentally measured viral growth statistics (see Fig. 2)
correspond to mean values and standard deviations pooled over all
12 individual passages p during experiment j. The corresponding
pooled means m(j) and standard deviations s(j) of passage times can be
computed from the model as follows [38]:
m(j)~
1
12
:
X
p
m j,pð Þ, ð9Þ
s(j)~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
12
X
p
s2 j,pð Þz
Xp{1
h~1
m j,pð Þ{m j,hð Þ
12
 2vuut : ð10Þ
Substituting eqs.(1)-(8), we use the statistical measures derived in
eqs.(9)-(10) to estimate model parameters (fold resistance towards
NVP (FR qð Þ) and the fitness deficits f qð Þ for single mutations q,
the growth rate of the respective baseline isolate r1, its susceptibility
towards NVP (IC50) and the probability rNRTI to encounter
inhibition by NRTIs with intensity (gNRTI), by minimizing the
weighted least squares deviation between model and data:
e Qð Þ~ argmin
Q
X
j
m(j){mexp(j)
mexp(j)
 !2
z
s(j){sexp jð Þ
sexp(j)
 2
, ð11Þ
were m(j) and s(j) denotes the predicted pooled mean passage times
and the corresponding pooled standard deviations respectively for
experimental set-up j, which were computed using eqs.(9)-(10).
Parameters mexp(j) and sexp jð Þ denote the experimental pooled mean
passage times and their standard deviations for experimental set-up j, as
shown in Fig. 2. The parameter set Q, which is optimized, is
determined by all mutational events that occurred in the respective
isolate and baseline parameters. For example, for isolate #1, this
includes the baseline parameters r1,IC50,rNRTI and gNRTI and
the parameters related to mutational events:
FR 188Cð Þ,FR 106Að Þ,FR 69Ið Þ,FR 108Ið Þ,FR 128Qð Þ,f 184Vð Þ
Parameter Estimation, Identifiability & Model Selection
Parameter estimation was run using constrained optimization
implemented in the MATLAB function lsqcurvefit (optimiza-
tion toolbox). Note that some unbounded parameters (e.g.
FR qð Þ&IC50) may not be reliably estimated if they appear in
conjunction, see eq. (2). In order to improve the estimation of these
parameters, we penalized unrealistically large values in the
objective function, i.e. eE Qð Þ~E Qð ÞzIC50zw:P
q[Q
log FR qð Þð Þ,
where wv1= qj j. This way, a resistance value FR qð Þw1 is only
estimated, if it improves the model significantly over a ‘no
resistance’ estimate FR qð Þ~1 (‘null model’). Also, estimation
would favor small IC50 values, which is justified, because all
baseline isolates were NVP-naive. While this change to the
objective function adds a (small) bias towards lower FR qð Þ values,
all fold resistance estimates have to be interpreted as lower
boundaries, i.e. FR(106A)$65 denotes that mutation V106A
yields at least 65-fold susceptibility reduction. Parameter estimates
for r1,IC50,rNRTI,gNRTI,f qð Þ were not altered by this modifica-
tion of the objective function.
Finally, we performed a model selection to investigate which
sub-set of parameters H5Q best explained the data. For example,
if a total number of two mutational events q1 and q2 were selected
in all experiments with the same isolate x, we took all of four
possible candidate models Hi into account: a model that takes both
mutational events q1 and q2 into account H1~ q1,q2f g, two models
that take either q1 or q2 into account (H2~ q1f g and H2~ q1f g)
and a ‘null’ model H4, which does not take any mutational events
HIV-1 Evolution During In Vitro RTI Drug Pressure
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into account. For each of the 2|q| candidate models Hi (in total
5280 models for all isolates), parameter estimation was performed
50 times with random start parameters to assess parameter
identifiability for each candidate model Hi. Finally, for each
isolate, the k-most informative models according to their AIC
(Akaike information criterion) [39] were chosen. The k-most
informative models had to exceed a relative likelihood of 0.45, in
comparison to the best model (lowest AIC). Parameter estimates
presented later in the manuscript are medians and 5th and 95th
percentiles based on the k-best models. A visual predictive check of
experimental- vs. predicted data (k-best models) is shown in Figure
S1. For clarity and ease-of-understanding, a diagram of the
parameter estimation and model selection procedure is depicted in
Figure S2 and the complete MATLAB source code is provided in
Material S1, including a short instruction on its application.
Results
Selection of Mutations by ADV, 3 TC, and NVP
Baseline isolates #1–5 (see Table 1) exhibited thymidine-
analogue-associated mutations (TAM): M41L, D67N, K70R,
L210W, T215F/Y, K219Q and 3 TC resistance (M184V) [40],
but there were no mutations associated with NNRTI resistance
including positions 100,101, 103, 106, 108, 179, 181, 188, 190,
225, 227, 230 and 236 [28,40,41]. In experiments with NVP,
substitutions at all of these positions were observed, except for
codons 100, 225, 230 and 236. The additional substitutions
observed at codons 69, 122, 128, 208, 218, 224 and 228 in our
NVP experiments have not previously been linked to NVP
resistance [28,40]. Isolates exposed to escalating doses of NVP
showed a gradual appearance/selection of one- to three new
NNRTI mutations (totalling 43 new mutations with NVP), see
Fig. 1. Of the newly detected mutations, 36 were at positions
previously reported in the context of NVP resistance [28,40,41].
Mutations at position 106 (V106 A/M/I) and V108 I were
eventually selected by NVP (experimental set-ups j[ C,D,E,Ff g).
Interestingly, different substitutions arose for the distinct isolates at
position 106, i.e. isolate #4 developed 106 M, whereas isolates #1
and #5 developed 106A and isolates #2/3 either developed 106A
or 106I. The mutation V106 M always appeared with L228 Q,
followed by F227 L in experiments with NVP and ADV
(experiments D & F) in isolate #4. Mutations Y181 C and
Y188 C were selected in isolates #2, 3, 4 & 5 and isolates #1, 2,
4 & 5 respectively. Other mutations occurred less frequently.
All isolates had the 184V mutation at baseline (Table 1), which
was always preserved in the presence of 3 TC, whereas the
reversion Mr184V occurred in 86% (12/14) of the passages
when 3 TC was absent (p,0.001). Interestingly, mutation H208Y
was de-selected in isolate #4, experiments j[ B,C,E,Ff g, but
selected in isolate #5, experiment B, see Fig. 1B. Pre-existing
TAM-1 mutations were deselected in isolate #4 C/Dr215Y
(Fig. 1A & Fig. 1C) and in isolate #5 Lr210W (Fig. 1C &
Fig. 1E). The mutation 210W was always deselected together with
Rr211K and in the presence of NVP, but in the absence of ADV
(experiments C & E). The TAM-2 mutation at position 67 S was
modified Nr67 S in isolate #2/3, experiments j[ A,C,E,Ff g.
Isolates #2 and #3 were derived from the same clinical isolate
with similar, but not identical evolutionary patterns that emerged
in serial passage experiments C, D & E (see Fig. 1C–E). This
suggests that chance mutation may occur with different evolu-
tionary consequences.
The average number of selected mutations is illustrated in
Figure 3A for the sequential passages (pooling data from all
passages and isolates). The average rate of resistance development
in passages 5–7 and 12 was significantly greater in experiments
with NVP than without NVP. The rate of new resistance
mutations in the NVP experiments was highest during passages
5–7 and 12.
Figure 3. Selection dynamics. A: Average number of mutations per passage in experiments with NVP (experimental set-ups C, D, E & F). Asterisks
indicate whether there were significantly more mutations (Wilcoxon rank sum test) than in the NVP-free experiments (experimental set-ups A & B).
*p,0.1, **p,0.05, ***p,0.01. B: Cumulative probability of detecting no mutation. The blue and red lines show the cumulative probability of not
detecting a mutation after the indicated numbers of passages (x-axis) in experiments where NVP was added with increasing concentrations (blue line;
experimental set-ups C, D, E & F) vs. experiments where no NVP was added (red line; experimental set-ups A & B).
doi:10.1371/journal.pone.0061102.g003
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The rate of mutation as time-to-event, with NVP, was
significantly greater than the rate of mutation without NVP. In
the presence of NVP, at least one mutation occurred after 8
passages, whereas at least one mutation occurred in only 47% of
all experiments without NVP by passage 8 (and in 66.6% of
experiments without NVP after 12 passages). The cumulative
Figure 4. Box plot of passage times for virus isolate#1,#2,#4 &#5 during experimental set-ups A & B (no drugs added vs. 1 mM
3 TC plus 2 mM ADV added) as indicated on the x-axis. The solid red horizontal lines indicate the respective median passage times, whereas
the boxes surrounding them indicate the range encompassed by the 25th and 75th percentiles. The whiskers denote the most extreme data points,
which are not considered outliers and the black dots indicate outliers. A: Viral passage times for isolate #1. B: Viral passage times for isolate #2. C:
Viral passage times for isolate #4. D: Viral passage times for isolate #5.
doi:10.1371/journal.pone.0061102.g004
Table 2. Estimated baseline parameters.
r0/ [1/day] IC50[mM] gNRTI rNRTI
Iso #1 0.42 (0.42, 0.42) 0.39 (0.37, 0.48) 0.65 (0.63, 0.67) 0.43 (0.28, 0.44)
Iso #2/3 0.39 (0.39, 0.39) 0.07 (0.07, 0.1) 0.99 (0.97, 0.99) 5.4e27 (4.7e27, 1.8e24)
Iso #4 0.33 (0.33, 0.33) 0.13 (0.07, 0.14) 0.99 (0.99, 0.99) 1.1e25 (3.8e26, 1.2e25)
Iso #5 0.36 (0.36, 0.36) 0.39 (0.39, 0.49) 0.99 (0.99, 0.99) 1e26 (9.9e27, 1.1e26)
r0/ (baseline growth rate in the absence of drugs), intensity- gNRTI and probability rNRTI of NRTI-induced effect at concentrations of 1 mM 3 TC and 2 mM ADV respectively
and lower-bound estimates for the susceptibility of baseline isolates towards NVP IC50. Indicated numbers are median estimates from the k-best models (see
Mathematical Methods) and their respective 5th–and 95th –percentiles (in brackets).
doi:10.1371/journal.pone.0061102.t002
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probability that no mutation appears is shown in Figure 3B. The
rate at which mutations appear is significantly higher (p,0.01)
with NVP.
Viral Growth Kinetics
The experimental single-passage times are shown in Figure 2
where the passage times with NVP at increasing concentrations
were compared to those without NVP. Most experiments with
NVP resulted in significantly longer passage times compared to
those without addition of drugs (experimental set-up A; see solid
horizontal bars in Figure 2). Remarkably, there was no significant
difference in mean passage times between experiments with NVP
(experimental conditions C, D, E & F) and experimental set-up B
(ADV and 3 TC at constant drug concentrations).
Addition of Low dose NRTIs Introduces Stochastic Viral
Growth Dynamics
In Figure 4A–D we compared viral growth dynamics without
drugs to growth in 1 mM 3 TC and 2 mM ADV. The addition of
3 TC and ADV did not significantly delay viral growth in isolates
#1, 2 & 4, suggesting that 1 mM 3 TC and 2 mM ADV did not
inhibit viral growth in the majority of passage-experiments.
However, for isolate #5 significantly longer passage times were
observed (p = 0.01) when 3 TC and ADV were added to the
medium. However, the variance of the passage times was significantly
increased for all isolates tested (p,0.05 for isolates #2 and #5 and
p,0.01 for isolates #1 and #4, see Fig. 4).
This initial evaluation of viral growth kinetics in the presence
and absence of 3 TC/ADV indicates a stochastic effect of 3 TC
and ADV. In order to account for this effect in the viral growth
model, we introduced the parameter rNRTI denoting the
probability of NRTI-effect (depending on the baseline isolate),
and a parameter describing the intensity of effect, denoted by
gNRTI. These parameters were estimated to be 0ƒgNRTIƒ1 with
probability 0ƒrNRTIƒ1 when NRTIs were added (experimental
set-ups j[ B,D,E,Ff g) and set to gNRTI~0, if NRTIs were not
added (experimental set-up: j[ A,Cf g), as described in the
Mathematical Methods section.
Estimating Drug Susceptibility and Fitness of Baseline
Isolates
Using the Mathematical Methods described earlier, we were able to
estimate key model parameters. In Table 2 the estimated growth
rates r and 50% inhibitory NVP concentrations IC50 are shown for
the respective baseline isolates.
All baseline isolates had fairly similar growth rates (range: 0.33–
0.42 day21), although isolate 1 seems to be slightly more fit (in
terms of the viral growth rate r), whereas isolate 4 is the least fit of
the four baseline isolates. The estimated median IC50 of the
baseline isolates ranged from 0.07 to 0.39 mM NVP, consistent
with published IC50 values for drug susceptible virus
(wt- IC50:0.1 mM [23]; corrected for protein binding).
The estimated intensity- and probability of NRTI effect
(parameters gNRTI and rNRTI respectively) are shown in Table 2.
For isolates #2, #3, #4 and #5, the estimated parameters
confirmed that the probability of NRTI inhibition is low
(rNRTI = 5.10
–7,10–5 and 10–6 respectively for isolates #2/3, #4
and #5), but the intensity of effect was quite pronounced
(gNRTI = 0.99 respectively for isolates #2/3, #4 and #5) at low
NRTI concentrations. In contrast, for isolate #1, parameters
relating to the efficacy of NRTIs were rNRTI = 0.43 (5
th percentile:
0.28; 95th percentile: 0.44) and gNRTI = 0.66 (5
th percentile: 0.63;
95th percentile: 0.67).
NVP Drug Resistance
Using the Mathematical Methods presented earlier, we estimated
the fold resistance FR(q), exerted by the individual mutations q (see
Table 3). As described in the Mathematical Methods section, we used
a model selection algorithm in order to choose the most
informative models (permutations of considered mutations) for
our parameter estimation. As a consequence, not all parameters
could be estimated. Mutations that were observed during final
passages did not allow the assessment of growth dynamics in
subsequent passages. Specifically, parameters FR(69I), FR(103N),
FR(122K), FR(128Q), FR(208Y) and FR(218G) were not identi-
fiable from the data and were thus not included into Table 3.
Resistance estimates were distinct for the four different baseline
isolates, indicating that pre-existing NRTI mutations may have
influenced the impact of subsequent mutations on NVP
susceptibility [42–45].
Table 3. Estimated lower-bounds of fold resistance against
NVP exerted by single amino acid substitutions in the distinct
genetic background of the baseline isolates.
Iso #1 Iso #2/3 Iso #4 Iso #5
FR(101E) n.s n.s 5 (2, 5) n.s.
FR(106A) 80 (52, 135) 176 (22, 195) n.s 21 (9, 47)
FR(106I) n.s 5 (3, 9) n.s n.s
FR(106M) n.s n.s 1 (1, 4) n.s
FR(108I) 25 (7, 26) 1 (1, 1) 7 (6, 65) 7 (3, 7)
FR(179I) n.s. 1 (1, 3) n.s. n.s.
FR(181C) 5 (4, 6) 7 (6, 41) n.i 13 (10, 13)
FR(190A) n.s 8 (7, 11) n.i n.s.
FR(181C/
190A)
n.s n.s 67 (59, 300) n.s.
FR(188C) 23 (4, 43) n.s. n.s 7 (2, 11)
FR(218E) n.s. 1 (1, 5) n.s. n.s.
FR(224K) n.s 1 (1, 5) n.s n.s.
FR(227L) n.s n.s 12 (7, 29) n.i.
FR(228Q) n.s n.s 128 (8, 423) n.s.
Values indicated are medians of all parameter estimates and the 5th and 95th
percentile of the estimates are indicated in brackets. ’n.s’ means ‘not selected’
and n.i. means parameter ‘not identifiable’. Parameters FR(69I), FR(103N),
FR(122K), FR(128Q), FR(208Y) and FR(218G) were not identifiable from the data
for any isolates and thus omitted from the table.
doi:10.1371/journal.pone.0061102.t003
Table 4. Estimated relative fitness deficit f(q) of mutations
present in the genetic background of baseline isolates
#1,#2/3,#4,#5.
Iso #1 Iso #2/3 Iso #4 Iso #5
f(184V) 0.79 (0.79, 0.79) 0.59 (0.59, 0.62) 0.65 (0.64, 0.65) 0.65 (0.65, 0.66)
f(215Y) n.ds n.ds 0.68 (0.68,0.68) n.ds
A small value (close to 0) denotes a large fitness loss, whereas a value close to 1
denotes no fitness deficit. Values indicated are medians of all parameter
estimates. The 5th and 95th percentile of estimates are indicated in brackets.
’n.ds’ means ‘not deselected’ and n.i. means parameter ‘not identifiable’.
Parameters f(67S), f(208H), f(35I) and f(210W/211K) could not be reliably
estimated from the data or were not significantly different from the value 1.
doi:10.1371/journal.pone.0061102.t004
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All isolates developed novel mutations at codon 106 in the
presence of NVP. Mutation V106 A was estimated to induce a
profound fold resistance for isolates #1 and #2/3 and in isolate
#4 ($80, $184 and $21 respectively). Substitution V106 I was
associated with at least 5-fold resistance, which was selected by
relatively low NVP concentrations of 0.04 mM in isolates #2/3.
According to our estimates (Table 3), the substitution V106 M in
isolate #4 elicited little resistance.
Mutation V108 I arose in all isolates at least once. V108 I
led to modest NVP resistance in isolate #4 and #5, whereas
moderate to strong resistance was conferred in isolate #1.
Mutation Y181 C appeared in all isolates, but the magnitude
of resistance conferred by this mutation could only be estimated
for isolates #1, #2/3 and #5, where it resulted in 5- to 13-fold
resistance. In isolate #4, Y181 C appeared simultaneously with
G190???A, which induced strong NVP resistance according to our
parameter estimates (FR$67).
Interestingly, mutation L228 Q (isolate #4) was estimated to
be associated with strong resistance development to NVP (Table 3)
by our parameter estimates. This mutation always occurred before
F227 L, which added a moderate fold resistance. Mutation
K103 N, which is the most commonly observed resistance
mutation to NVP in the clinic, appeared only during the final
passage in experimental set-up D [NVP +3 TC] with isolate #2.
Hence, a phenotype associated with this mutation was not
observed and FR(103N) could not be estimated.
Effect of Baseline Mutations on Viral Fitness
The following back mutations or reversals were observed during
the passage experiments:
qM{Mr184V, Nr67S, Hr208Y, C/Dr215Y, Vr35I,
Lr210W, Rr211K}.
Only the de-selection Mr184V significantly improved viral
fitness in all isolates according to our parameter estimates (Table 4).
Interestingly, the number of distinct mutations undergoing reversal
was inversely correlated with our estimates of the growth rate r, i.e.
the ‘‘fittest’’ baseline isolates (largest parameter r0/) had the fewest
distinct mutations reversing back to wild type (1, 2, 4, 2 distinct
deselected mutations for isolates #1, #2/3, #4 and #5
respectively).
Parameter estimation (see Table 4) indicated that 184V
conferred the greatest selective disadvantage of all mutations
tested. The relative fitness estimated for the individual isolates
ranged from 59% to 79% for the distinct isolates, which is
generally consistent with previous in vivo estimates [46] and
predictions from mechanistic mathematical models of HIV-1
DNA polymerization [7].
Although all baseline isolates carried resistance mutations at
position 215, a change at amino acid position 215 (Cr215Y and
Dr215Y) was observed only in isolate # 4. In Table 4, we
estimated a relative fitness of 68% attributable to amino acid 215Y
in isolate #4.
Fitness values f(67S), f(208H), f(35I) and f(210W/211K) were
not included in the k-most informative models (see Mathematical
Methods) and could thus not be estimated from the data.
Discussion
The selection of drug resistance by a combination of drugs
in vitro demonstrated complex evolutionary trajectories. Mathe-
matical modelling of the passage experiments and the viral growth
dynamics enabled estimation of fitness and drug resistance
associated with mutational events.
Epistasis and Combination Passage Experiments
Drug resistance emerging during antiretroviral combination
therapy is influenced by viral genetic polymorphisms, random
effects, and epistasis. The latter is a phenomenon where the
phenotype induced by one mutation is modified by one or several
other mutations [47]. Epistasis may be of particular clinical
relevance in NRTI and NNRTI therapies, where the reverse
transcriptase is targeted by different drugs [3]. Mutations resulting
from exposure to one RT inhibitor may alter the phenotype of
mutations selected by another RT inhibitor, through functional or
conformational perturbation of the enzyme. Epistasis in HIV-1 has
been studied in the absence of drugs [47] and after application of
single drugs [7,48]. Due to the complexity of the laboratory work
required and the many possible permutations resulting from a
variety of parameters, passage experiments using multiple drugs
simultaneously have not yet been studied in detail. Here,
combination passage experiments were performed in four clinical
isolates from NRTI experienced, NNRTI-naive patients. In
contrast to site directed mutagenesis to introduce resistance
mutations into clonal laboratory isolates, clinical isolates were
subject to the gradual and ‘‘natural’’ evolutionary dynamics in the
serial passage experiments. Consensus sequencing after each
passage allowed the detection of variants that may be favored by
in vivo selection.
The isolates harbouring amino acid substitutions selected by
NRTI exposure showed very distinct (strain-specific) evolutionary
trajectories. Among identical amino acid substitutions we could
observe distinct (strain-specific) effects on drug resistance (see
Tables 2 & 3). Such strain-specific differences are likely governed
by epistatic interactions between pre-existing and novel emerging
mutations, as reported elsewhere [13,14]. Epistasis in combination
therapy complicates genotype-phenotype relationships because
single mutations may have different effects on drug resistance in
different genetic backgrounds.
The divergent evolution of isolates #2 and #3 (derived from
the same baseline sample), on the other hand, stresses the impact
of chance mutation on evolutionary trajectories.
Phenotypic Attributes of Acquired NVP Resistance
Mutations
Epistasis could be the mechanism behind the selective amino
acid substitution at RT codon 106 in isolate #4, which exclusively
developed the V106 M (GTG -. ATG) substitution, although
V106 A (GTG -. GCG) could also have occurred by random
mutation. Interestingly, V106 M always appeared together with
L228 Q (either before- or after), followed by F227 L in
experiments with NVP and ADV (experiments D & F) in the
specific genetic background of isolate #4. The L228 Q is a rare
mutation associated with co-administration of NRTIs and
NNRTIs [28], particularly when the NRTI is a dATP analogue
such as ADV. In our case it only (and always) appears in isolate
#4, i.e. in 2/2 experiments when NVP was co-administered with
ADV (experiments D & F), irrespective of the presence of 3 TC.
The L228 Q mutation results in a change from a non-polar/
hydrophobic- to a strongly polar amino acid in direct proximity to
the NNRTI binding pocket [49], possibly modulating the binding
of NVP, which could induce resistance as predicted in Table 3.
In contrast, isolates #1, #2/3 and isolate #5 developed
V106 A, which mediate strong resistance [28] in agreement with
our estimates, see Table 3. Although previous reports suggest that
the V106 I mutation alone does not confer resistance to NVP
in vitro [50,51], we estimated a low-to-moderate resistance by this
mutation, which may be explained by the genetic background of
isolates #2/3.
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It may be possible that appearance of the K103 N mutation
was restricted by multiple pre-existing RT mutations. Notably, the
K103 N may contribute little in terms of resistance to NVP in
the presence of multiple TAMs and 3 TC resistance (such as RT
mutations: M41L, D67N, M184V, L210W, T215Y, K219Q,
P236P/L) [52], see Fig. 1.
Previous reports provide evidence that the Y181 C mutation is
associated with moderate-to-high level NVP resistance [28], while
our estimates for isolates #1, #2/3 and #5 suggests a low-to-
moderate resistance attributable to this mutation. Although
considered a major resistance mutation against NVP, [28,40], in
isolate #3, the estimated impact of G190 A was only moderate.
In agreement with other data [28,52], mutation Y188 C induced
moderate to strong NVP resistance. This mutation however, was
only selected in isolates #1 and #5.
Phenotypic Attributes of De-selected (Fitness) Mutations
The 184 V mutation was deselected in all combination passage
experiments not including 3 TC and conferred a significant
selective disadvantage in all isolates tested, which is exploited in
some treatment lines that include 3 TC despite the M184V
mutations. However, the degree of the fitness deficit was different
for the four distinct baseline isolates, suggesting, again, epistatic
interactions, as described previously [53,54]. The statistical
analysis of the experiments suggested that addition of 1 mM
3 TC and 2 mM ADV to the drug resistant viruses used in the
experiments did not significantly inhibit viral growth. Further-
more, the analysis suggested that M184V, which was present in all
baseline isolates, persisted in the presence of 1 mM 3 TC and
reverted in its absence. The continued administration of 3 TC to
preserve 184V is common in salvage strategies [18,55].
Mutations C/Dr215Y are considered ‘‘reversion’’ mutations
that have been observed in vivo in the absence of zidovudine (AZT)
[56,57] and in untreated individuals infected with 215F/Y-
containing (AZT-resistant) variants [57]. Here, ‘‘reversion’’ was
observed in the genetic context of isolate #4. This ‘‘reversion’’
could recover an apparently large fitness loss associated with 215Y
(relative fitness 68%, see Table 3). AZT-susceptible strains
containing 215C/D were reported to be as fit as the WT virus
in the absence of the drug [58], but retain the potential for the
rapid emergence of high-level AZT resistance, through a single
nucleotide substitution at codon 215 to become the resistant 215Y
(by contrast, the conversion of wild type to resistant T215 Y
requires 2 nucleotide substitutions).
Multidrug passage experiments with escalating drug concentra-
tions may reproduce clinical scenarios where concentrations vary
over time and facilitate the development of drug resistance [59].
The emergence of drug resistance, despite high genetic barriers,
has been attributed to heterogeneous pharmacokinetics in multiple
physiologic compartments [60], resulting in sub-inhibitory con-
centrations of drugs [61–63]. In our passage experiments, such
multi-stage scenarios can be reproduced: resistance may evolve
under conditions allowing residual replication (the respective first
passages) and then be selected further in subsequent passages
favoring selection through increased selective pressure. The drug
combination assay may be suitable to study the evolution of very
complex resistance patterns, such as TAMs, the Q151M complex,
resistance to some protease inhibitors or multidrug resistance to
NNRTI+NRTI combinations.
Most importantly, in vitro combination passage experiments in
conjunction with novel in silico analysis methodologies can
contribute to an improved understanding of the complex evolution
of drug resistance in clinical studies and individuals. Mathematical
tools to estimate phenotypic parameters, including resistance and
fitness, may provide new insights for designing effective drug
combinations.
Supporting Information
Figure S1 Visual predictive checks of predicted (y-axis) versus
observed (x-axis) data points. A: Means of mean first passage times
m(j)and B: their standard deviations s jð Þ. The distinct markers
indicate the different patient isolates: leftward-, upward-, right-
ward- and downward-pointing triangles indicate data/predictions
from/for isolates #1, #2/3, #4 and #5. Colours indicate the
different experimental set-ups, e.g. red, cyan, blue, yellow,
magenta and green denote experimental set-ups A-F respectively.
Vertical bars indicate the range of predictions spanned by the 5th
and 95th percentile of all model evaluations.
(PDF)
Figure S2 Organization of the source code (Material S1) for the
estimation of phenotypic parameters from passage experiments.
(PDF)
Material S1 MATLAB source code of the developed param-
eter inference procedure described in the Mathematical Methods
section.
(ZIP)
Acknowledgments
The authors thank Mark Winters for his advice and Kristi Cooley, Aimee
Geissler, and Yvette Girard for their excellent technical assistance in the
laboratory.
Author Contributions
Conceived and designed the experiments: TCM. Performed the experi-
ments: BAR. Analyzed the data: BAR MvK KPY. Contributed reagents/
materials/analysis tools: TCM DKK RWS MvK KPY CS. Wrote the
paper: BAR MvK KPY. Conceived and designed the mathematical
methods: MvK KPY CS. Provided important intellectual input to the
manuscript: CS DKK RWS. Approved the final version of the manuscript:
BAR KPY DKK RWS CS MvK TCM.
References
1. Martinez-Cajas JL, Wainberg MA (2008) Antiretroviral therapy : optimal
sequencing of therapy to avoid resistance. Drugs 68: 43–72.
2. Reekie J, Mocroft A, Ledergerber B, Beniowski M, Clotet B, et al. (2010) History
of viral suppression on combination antiretroviral therapy as a predictor of
virological failure after a treatment change. HIV Med 11: 469–478.
3. Chou R, Fu R, Huffman LH, Korthuis PT (2006) Initial highly-active
antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse
transcriptase inhibitor: discrepancies between direct and indirect meta-analyses.
Lancet 368: 1503–1515.
4. Esnouf R, Ren J, Ross C, Jones Y, Stammers D, et al. (1995) Mechanism of
inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat
Struct Biol 2: 303–308.
5. Spence RA, Kati WM, Anderson KS, Johnson KA (1995) Mechanism of
inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science
(New York, N Y ) 267: 988–993.
6. Frank M, von Kleist M, Kunz A, Harms G, Schutte C, et al. (2011) Quantifying
the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child
transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and
viral dynamic analysis to predict clinical outcomes. Antimicrob Agents
Chemother 55: 5529–5540.
7. von Kleist M, Metzner P, Marquet R, Schutte C (2012) HIV-1 polymerase
inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy,
susceptibility and resistance selection. PLoS Comput Biol 8: e1002359.
HIV-1 Evolution During In Vitro RTI Drug Pressure
PLOS ONE | www.plosone.org 11 April 2013 | Volume 8 | Issue 4 | e61102
8. Fisher EJ, Chaloner K, Cohn DL, Grant LB, Alston B, et al. (2001) The safety
and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a
randomized, placebo-controlled trial. AIDS 15: 1695–1700.
9. DHHS (2012) Guidelines for the use of antiretroviral agents in HIV-1-infected
adults and adolescents Available: http://wwwaidsinfonihgov/ContentFiles/
AdultandAdolescentGLpdf.1–239. PP. Accessed 2012 Apr 26.
10. Sierra-Aragon S, Walter H (2012) Targets for inhibition of HIV replication:
entry, enzyme action, release and maturation. Intervirology 55: 84–97.
11. Herman BD, Votruba I, Holy A, Sluis-Cremer N, Balzarini J (2010) The acyclic
2,4-diaminopyrimidine nucleoside phosphonate acts as a purine mimetic in
HIV-1 reverse transcriptase DNA polymerization. J Biol Chem 285: 12101–
12108.
12. Sluis-Cremer N, Sheen CW, Zelina S, Torres PS, Parikh UM, et al. (2007)
Molecular mechanism by which the K70E mutation in human immunodefi-
ciency virus type 1 reverse transcriptase confers resistance to nucleoside reverse
transcriptase inhibitors. Antimicrob Agents Chemother 51: 48–53.
13. Weinreich DM, Watson RA, Chao L (2005) Perspective: Sign epistasis and
genetic constraint on evolutionary trajectories. Evolution 59: 1165–1174.
14. Breen MS, Kemena C, Vlasov PK, Notredame C, Kondrashov FA (2012)
Epistasis as the primary factor in molecular evolution. Nature 490: 535–538.
15. von Kleist M, Menz S, Stocker H, Arasteh K, Schutte C, et al. (2011) HIV
quasispecies dynamics during pro-active treatment switching: impact on multi-
drug resistance and resistance archiving in latent reservoirs. PLoS One 6:
e18204.
16. Gianotti N, Tiberi S, Menzo S, Danise A, Boeri E, et al. (2008) HIV-1
replication capacity and genotype changes in patients undergoing treatment
interruption or lamivudine monotherapy. J Med Virol 80: 201–208.
17. Buckheit RW Jr (2004) Understanding HIV resistance, fitness, replication
capacity and compensation: targeting viral fitness as a therapeutic strategy.
Expert Opin Investig Drugs 13: 933–958.
18. Castagna A, Danise A, Menzo S, Galli L, Gianotti N, et al. (2006) Lamivudine
monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant
virus: a randomized pilot study (E-184V study). AIDS 20: 795–803.
19. Rath B, Olshen RA, Halpern J, Merigan TC (2012) Persistence versus Reversion
of 3 TC Resistance in HIV-1 Determine the Rate of Emergence of NVP
Resistance. Viruses 4: 1212–1234.
20. Melikian GL, Rhee SY, Taylor J, Fessel WJ, Kaufman D, et al. (2012)
Standardized comparison of the relative impacts of HIV-1 reverse transcriptase
(RT) mutations on nucleoside RT inhibitor susceptibility. Antimicrob Agents
Chemother 56: 2305–2313.
21. Palmer S, Shafer RW, Merigan TC (1999) Highly drug-resistant HIV-1 clinical
isolates are cross-resistant to many antiretroviral compounds in current clinical
development. AIDS 13: 661–667.
22. Tang MW, Shafer RW (2012) HIV-1 antiretroviral resistance: scientific
principles and clinical applications. Drugs 72: e1–25.
23. Merluzzi VJ, Hargrave KD, Labadia M, Grozinger K, Skoog M, et al. (1990)
Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase
inhibitor. Science 250: 1411–1413.
24. Winters MA, Schapiro JM, Lawrence J, Merigan TC (1998) Human
immunodeficiency virus type 1 protease genotypes and in vitro protease
inhibitor susceptibilities of isolates from individuals who were switched to other
protease inhibitors after long-term saquinavir treatment. J Virol 72: 5303–5306.
25. Nijhuis M, Boucher CA, Schuurman R (1995) Sensitive procedure for the
amplification of HIV-1 RNA using a combined reverse-transcription and
amplification reaction. Biotechniques 19: 178–180, 182.
26. Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, et al. (1996) The effect
of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected
patients. Ann Intern Med 124: 1039–1050.
27. Winters MA, Coolley KL, Girard YA, Levee DJ, Hamdan H, et al. (1998) A 6-
basepair insert in the reverse transcriptase gene of human immunodeficiency
virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest
102: 1769–1775.
28. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, et al. (2003) Human
immunodeficiency virus reverse transcriptase and protease sequence database.
Nucleic Acids Res 31: 298–303.
29. Allen LJS (2011) An introduction to stochastic processes with applications to
biology. Boca Raton, FL: Chapman & Hall/CRC. xxiv, 466 p. p.
30. Perelson AS, Nelson PW (1999) Mathematical analysis of HIV-1 dynamics
in vivo. Siam Review 41: 3–44.
31. von Kleist M, Menz S, Huisinga W (2010) Drug-class specific impact of
antivirals on the reproductive capacity of HIV. PLoS Comput Biol 6: e1000720.
32. Bonate PL (2006) Pharmacokinetic-Pharmacodynamic Modeling and Simula-
tion. New York, NY: Springer.
33. Norris JR (1998) Markov chains. Cambridge, UK; New York: Cambridge
University Press. xvi, 237 p. p.
34. Gardiner CW (2004) Handbook of stochastic methods for physics, chemistry,
and the natural sciences. Berlin; New York: Springer-Verlag. xvii, 415 p. p.
35. Engblom S (2006) Computing the moments of high dimensional solutions of the
master equation. Applied Mathematics and Computation 180: 498–515.
36. Gillespie DT (1992) Markov processes: an introduction for physical scientists.
San Diego: Academic Press.
37. Hogg RV, McKean JW, Craig AT (2013) Introduction to mathematical
statistics. Boston: Pearson. x, 694 p.
38. Goon A (1962) Fundamentals of statistics. Calcutta,: World Press. 401 p.
39. Bonate PL (2011) Pharmacokinetic-pharmacodynamic modeling and simulation.
New York: Springer.
40. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, et al. (2011) 2011
update of the drug resistance mutations in HIV-1. Top Antivir Med 19: 156–
164.
41. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, et al. (2009) Drug
resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009
update. PLoS One 4: e4724.
42. Shulman N, Zolopa AR, Passaro D, Shafer RW, Huang W, et al. (2001)
Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors
in treatment-experienced HIV-infected patients: impact on virological response
to efavirenz-based therapy. AIDS (London, England) 15: 1125–1132.
43. Shulman NS, Bosch RJ, Mellors JW, Albrecht MA, Katzenstein DA (2004)
Genetic correlates of efavirenz hypersusceptibility. AIDS (London, England) 18:
1781–1785.
44. Katzenstein DA, Bosch RJ, Hellmann N, Wang N, Bacheler L, et al. (2003)
Phenotypic susceptibility and virological outcome in nucleoside-experienced
patients receiving three or four antiretroviral drugs. AIDS (London, England)
17: 821–830.
45. Bosch RJ, Downey GF, Katzenstein DA, Hellmann N, Bacheler L, et al. (2003)
Evaluation of cutpoints for phenotypic hypersusceptibility to efavirenz. AIDS
(London, England) 17: 2395–2396.
46. Martinez-Picado J, Morales-Lopetegi K, Wrin T, Prado JG, Frost SD, et al.
(2002) Selection of drug-resistant HIV-1 mutants in response to repeated
structured treatment interruptions. AIDS 16: 895–899.
47. Bonhoeffer S, Chappey C, Parkin NT, Whitcomb JM, Petropoulos CJ (2004)
Evidence for positive epistasis in HIV-1. Science (New York, N Y ) 306: 1547–
1550.
48. Martinez JP, Bocharov G, Ignatovich A, Reiter J, Dittmar MT, et al. (2011)
Fitness ranking of individual mutants drives patterns of epistatic interactions in
HIV-1. PLoS One 6: e18375.
49. Ren J, Stammers DK (2008) Structural basis for drug resistance mechanisms for
non-nucleoside inhibitors of HIV reverse transcriptase. Virus Res 134: 157–170.
50. Gatanaga H, Ode H, Hachiya A, Hayashida T, Sato H, et al. (2010)
Combination of V106I and V179D polymorphic mutations in human
immunodeficiency virus type 1 reverse transcriptase confers resistance to
efavirenz and nevirapine but not etravirine. Antimicrob Agents Chemother 54:
1596–1602.
51. Bacheler L, Jeffrey S, Hanna G, D’Aquila R, Wallace L, et al. (2001) Genotypic
correlates of phenotypic resistance to efavirenz in virus isolates from patients
failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 75: 4999–
5008.
52. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, et al. (2000) A novel
phenotypic drug susceptibility assay for human immunodeficiency virus type 1.
Antimicrob Agents Chemother 44: 920–928.
53. Cong ME, Heneine W, Garcia-Lerma JG (2007) The fitness cost of mutations
associated with human immunodeficiency virus type 1 drug resistance is
modulated by mutational interactions. J Virol 81: 3037–3041.
54. Sharma PL, Nurpeisov V, Hernandez-Santiago B, Beltran T, Schinazi RF
(2004) Nucleoside inhibitors of human immunodeficiency virus type 1 reverse
transcriptase. Curr Top Med Chem 4: 895–919.
55. Campbell TB, Shulman NS, Johnson SC, Zolopa AR, Young RK, et al. (2005)
Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1
infection. Clin Infect Dis 41: 236–242.
56. Goudsmit J, de Ronde A, de Rooij E, de Boer R (1997) Broad spectrum of
in vivo fitness of human immunodeficiency virus type 1 subpopulations differing
at reverse transcriptase codons 41 and 215. J Virol 71: 4479–4484.
57. Yerly S, Rakik A, De Loes SK, Hirschel B, Descamps D, et al. (1998) Switch to
unusual amino acids at codon 215 of the human immunodeficiency virus type 1
reverse transcriptase gene in seroconvertors infected with zidovudine-resistant
variants. J Virol 72: 3520–3523.
58. de Ronde A, van Dooren M, van Der Hoek L, Bouwhuis D, de Rooij E, et al.
(2001) Establishment of new transmissible and drug-sensitive human immuno-
deficiency virus type 1 wild types due to transmission of nucleoside analogue-
resistant virus. J Virol 75: 595–602.
59. Kepler TB, Perelson AS (1998) Drug concentration heterogeneity facilitates the
evolution of drug resistance. Proc Natl Acad Sci U S A 95: 11514–11519.
60. Arora P, Dixit NM (2009) Timing the emergence of resistance to anti-HIV drugs
with large genetic barriers. PLoS Comput Biol 5: e1000305.
61. Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentre F, et al. (2010) Intracellular
Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their
Correlation with Drug Action. Clinical pharmacokinetics 49: 17–45.
62. Cohen J (2011) HIV/AIDS research. Tissue says blood is misleading, confusing
HIV cure efforts. Science (New York, N Y ) 334: 1614.
63. North TW, Higgins J, Deere JD, Hayes TL, Villalobos A, et al. (2010) Viral
sanctuaries during highly active antiretroviral therapy in a nonhuman primate
model for AIDS. Journal of virology 84: 2913–2922.
HIV-1 Evolution During In Vitro RTI Drug Pressure
PLOS ONE | www.plosone.org 12 April 2013 | Volume 8 | Issue 4 | e61102
